Access to Combination Therapies in Exchanges

Combination therapies are medications that contain two or more pharmaceutical ingredients in a single dosage form (e.g., tablet, capsule) for the treatment of a condition. Oftentimes, patients living with chronic conditions—such as HIV and diabetes—rely on combination therapies because they reduce the number of medications or dosages a patient must take, which can increase adherence and clinical efficacy.

Strengthening the U.S.-Canada Relationship Through Innovative Partnerships

09.18.14 | By

Usually, when U.S. Secretary of Commerce Penny Pritzker holds a meeting with her Canadian counterpart, she meets with Minister of International Trade Edward Fast due to their overlapping issue areas. However, this week Secretary Pritzker will host a rare meeting with Canada’s Minister of Industry James Moore.

New Reports Demonstrate the Importance of Biopharmaceutical Industry Exports to U.S. Economy

09.05.14 | By

Earlier this week, the U.S. Department of Commerce released two new reports detailing the extraordinary impact that exports have on our economy. The new data revealed that exports supported more than 11 million jobs within the U.S.

Driving Amazing R&D Progress

09.02.14 | By

We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.

One Stop for Innovation: PhRMA’s New

08.26.14 | By

It’s likely many of us have paused to think about what life would have been like in a bygone time and felt thankful for the modern comforts we enjoy, from refrigeration to cell phones. When looking at the progress we’ve made and the comforts we enjoy, medical innovation should be at the top of the list. Over the past 100 years, life expectancy has surpassed 80 years, devastating diseases have been eradicated and quality of life has dramatically improved.

Debunking the Myths of Treating Hepatitis C

08.05.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)

Medicare Part D Continues to Be A Success

08.04.14 | By

Medicare Part D continues to be a success for beneficiaries.

Week in Review: The Age-Old Tale of Cost & Value

08.01.14 | By

This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.

Modi’s New Era Has Begun

07.31.14 | By

Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S. and India since Modi’s election in May.

Weighing-in on the Cost and Value of Innovation

07.31.14 | By

Earlier this week, PhRMA participated in the Wall Street Journal’s first tweet chat hosted by Ed Silverman, who spearheads the publication’s blog, Pharmalot.


Subscribe to RSS - Opinion